# US 2019/0292597 A1 · Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292597 A1
- Document ID: US20190292597A1
- Status: Published application
- Kind: A1
- Application number: 16/411,066
- Filed: 2019-05-13
- Published: 2019-09-26
- Earliest claimed: 2012-03-20
- Assignees: University of Washington through its Center for Commercialization
- Applicants: University of Washington Through Its Center for Commercialization
- Inventors: Jesse Salk; Lawrence A. Loeb; Michael Schmitt
- Web page: https://patentgrep.com/patent/US20190292597A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6869: Methods for sequencing
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A method, comprising:
a) providing a population of circulating DNA molecules obtained from a bodily sample from a subject;
b) converting the population of circulating DNA molecules into a population of non-uniquely tagged parent polynucleotides, wherein each of the non-uniquely tagged parent polynucleotides comprises (i) a sequence from a circulating DNA molecule of the population of circulating DNA molecules, and (ii) an identifier sequence comprising one or more polynucleotide barcodes, such that each non-uniquely tagged parent polynucleotide is substantially unique with respect to other non-uniquely tagged parent polynucleotides in the population;
c) amplifying the population of non-uniquely tagged parent polynucleotides to produce a corresponding population of amplified progeny polynucleotides;
d) sequencing the population of amplified progeny polynucleotides to produce a set of sequence reads;
e) mapping sequence reads of the set of sequence reads to a reference sequence;
f) grouping the sequence reads into families, each of the families comprising sequence reads comprising the same identifier sequence and having the same start and stop positions, whereby each of the families comprises sequence reads amplified from the same non-uniquely tagged parent polynucleotide;
g) at each genetic locus of a plurality of genetic loci in the reference sequence, collapsing sequence reads in each family to yield a base call for each family at the genetic locus; and
h) determining a frequency of one or more bases called at the locus from among the families.

### Claim 38 (depends on 37)

The method of claim 37, further comprising detecting, at one or more loci, one or more of at least one single nucleotide variant and at least one copy number variant.

### Claim 39 (depends on 37)

The method of claim 37, wherein converting comprises any of blunt-end ligation, sticky end ligation, PCR, ligation-based PCR, single strand ligation and circularization to a single strand.

### Claim 40 (depends on 37)

The method of claim 37, wherein the reference sequence comprises a sequence from a human reference genome.

### Claim 41 (depends on 37)

The method of claim 37, wherein determining the frequency comprises detecting a rare mutation.

### Claim 42 (depends on 37)

The method of claim 37, further comprising generating a set of consensus sequences from the sequence reads, wherein determining the frequency of one or more bases comprises detecting a presence of sequence variations in the set of consensus sequences compared with the reference sequence.

### Claim 43 (depends on 37)

The method of claim 37, further comprising filtering out sequence reads that fail to meet a quality threshold.

### Claim 44 (depends on 37)

The method of claim 37, further comprising selectively enriching regions from a genome or transcriptome of the subject prior to sequencing.

### Claim 45 (depends on 37)

The method of claim 37, further comprising removing a subset of the sequence reads from further analysis prior to (e).

### Claim 46 (depends on 37)

The method of claim 37, wherein the plurality of circulating DNA molecules includes a genetic variant having a variant frequency lower than about 1% or lower than about 0.01%.

### Claim 47 (depends on 37)

The method of claim 37, wherein the plurality of circulating DNA molecules includes a genetic variant having a variant frequency as low as about 0.01% or as low as about 0.03%.

### Claim 48 (depends on 37)

The method of claim 37, wherein an error rate of the base call of each family determined in step (g) is lower than about 1×10−6 or is as low as about 1.2×10−9.

### Claim 49 (depends on 37)

The method of claim 37, wherein an error rate of the base call of each family determined in step (g) is no more than about 1.5×10−4 or about 3.5×10−5.

### Claim 50 (depends on 37)

The method of claim 37, wherein the circulating DNA molecules are nucleic acid-based serum biomarkers.

### Claim 51 (depends on 37)

The method of claim 37, wherein the identifier sequence comprises a polynucleotide barcode selected from about 2 to about 256 distinct barcode sequences.

### Claim 52 (depends on 37)

The method of claim 37, wherein the identifier sequence comprises a polynucleotide barcode selected from more than 256 distinct barcode sequences.

### Claim 53 (depends on 37)

The method of claim 37, wherein the distinct barcode sequences are contained within a library generated from oligonucleotides comprising known sequences.

### Claim 54 (depends on 37)

The method of claim 37, wherein said non-uniquely tagged parent polynucleotide can be differentiated from other non-uniquely tagged parent polynucleotides using a combination of at least a first non-unique polynucleotide barcode at a first end of said circulating DNA molecule and a second non-unique polynucleotide barcode at a second end of said circulating DNA molecule.

### Claim 55 (depends on 37)

The method of claim 37, wherein the sequence reads are grouped into families based on i) the polynucleotide barcode and ii) at least one of: sequence information at a beginning of the sequence from the circulating DNA molecule and sequence information at an end of the sequence from the circulating DNA molecule.

### Claim 56 (depends on 62)

The method of claim 62, wherein the population of circulating DNA molecules comprises double-stranded molecule, and wherein the identifier sequence further comprises a strand identifier, and wherein, for each family of sequence reads amplified from the same non-uniquely tagged parent polynucleotide grouped in step (f), the method further comprises determining if the family has at least one sequence read from each strand of the double-stranded molecule using the strand identifier.

### Claim 57 (depends on 37)

The method of claim 37, wherein the circulating DNA molecules are double-stranded molecules, and wherein for each of a plurality of families, the method further comprises:
confirming the presence of at least one sequence read from each strand of the double-stranded molecule; and
comparing the at least one sequence read obtained from one strand to the at least one sequence read from the other strand to form a consensus sequence of the double-stranded molecule,
wherein the consensus sequence comprises only nucleotide bases at which the sequence of both strands of the double-stranded molecule are in agreement, such that a base call occurring at a particular position in the consensus sequence is identified as a true base call.

### Claim 58

A method, comprising:
a) attaching a set of molecular tags to a population of circulating DNA molecules obtained from a bodily sample of a subject to produce a population of tagged original DNA molecules, wherein a plurality of the tagged original DNA molecules has identical molecular tags, and wherein each tagged original DNA molecule is substantially unique with respect to other tagged original DNA molecules in the population;
b) amplifying the population of tagged original DNA molecules to produce a corresponding population of DNA molecule amplicons;
c) sequencing the population of DNA molecule amplicons to produce a set of sequence reads;
d) mapping sequence reads of the set of sequence reads to a reference sequence;
e) grouping the sequence reads into families based on i) the molecular tag and ii) sequence information derived from the circulating DNA molecule, whereby each of the families comprises sequence reads amplified from the same tagged original DNA molecule;
f) for each genetic locus in a set of genetic loci in the reference sequence, collapsing sequence reads in each family to provide an error-corrected consensus sequence read for each family at the genetic locus; and
g) determining a frequency of one or more genetic variants at the locus from among the families.

### Claim 59 (depends on 58)

The method of claim 58, further comprising selectively enriching regions from the subject's genome or transcriptome prior to sequencing.

### Claim 60 (depends on 58)

The method of claim 58, selectively enriching at least one of tagged original DNA molecules and DNA molecule amplicons for a subset of tagged polynucleotides that map to one or more genetic loci in the reference sequence.

### Claim 61 (depends on 58)

The method of claim 58, further comprising detecting, at one or more loci, at least one single nucleotide variant or at least one copy number variant.

### Claim 62 (depends on 58)

The method of claim 58, wherein determining the frequency comprises detecting a rare mutation.

### Claim 63 (depends on 58)

The method of claim 58, wherein the circulating DNA molecules are nucleic acid-based blood biomarkers.

### Claim 64 (depends on 58)

The method of claim 58, wherein the circulating DNA molecules are derived from neoplastic cells.

### Claim 65 (depends on 58)

The method of claim 58, wherein the set of molecular tags comprises about 2 to about 256 distinct molecular tags.

### Claim 66 (depends on 58)

The method of claim 58, wherein the set of molecular tags comprises more than 256 distinct molecular tags.
